Bringing Our Innovation in Drug Discovery to the World
The Japan Pharmaceutical Manufacturers Association (JPMA) We contribute to improving the health and medical quality of people around the world through the creation of novel pharmaceutical products.
The Japan Pharmaceutical Manufacturers Association (JPMA) is an organization representing the 72 research and development (R&D)-oriented pharmaceutical manufacturers. We aim to continue to contribute to improving the health and medical care of people in Japan and around the world through innovative pharmaceutical products.
The environment surrounding the pharmaceutical industry is changing rapidly, including changes in the age composition due to a low birth rate and an aging population, globalization of the pharmaceutical market and emerging technology such as regenerative medicine. Additionally, various public policies regarding drug pricing, taxation, and participation in the Trans-Pacific Partnership (TPP) are factors contributing to such environmental changes. However, despite this situation, our responsibility and mission in the healthcare industry will never change.
We launched “JPMA Industry Vision 2025” which leads the JPMA and the member companies towards our shared goal. We will pursue drug discovery innovation for developing personalized medicine, predictive medical technology and preventive medicine. Outcomes of our efforts will be delivered to patients and their families around the world. As a result of those activities, we, the pharmaceutical industry, contribute to addressing the burdens of an aging society.
Towards our vision, we contribute to advocate an appropriate assessment scheme for innovation; appropriate protection of innovative drugs based on intellectual property rights; and improvement of the R&D environment.
We continue dialogue with our stakeholders to pursue both access to medicines and sustainable healthcare and social security system.